Substituted indazoles for targeting Hsp90

Patent metadata

Field	Value
Publication number	US-9738643-B2
Application number	US-201314419965-A
Country	US
Kind code	B2
Filing date	Mar 14, 2013
Priority date	Aug 6, 2012
Publication date	Aug 22, 2017
Grant date	Aug 22, 2017

Abstract

Described herein are substituted indazoles that may selectively bind to Hsp90, methods of using the compounds, and kits including the compounds. The compounds may include detection moieties such as fluorophores that may allow for selective detection of Hsp90 in a sample. Suitable compounds include those of formula (II):

First claim

The invention claimed is:

1. A compound of formula (I):
A-X 1 -L-X 2 —B   (I)

wherein:
A is a heat shock protein 90 binding component;
X 1 is selected from the group consisting of —NH—, —O—, —S—, —C(O)— and —S(O) 2 —;
X 2 is selected from the group consisting of —NR—, —O—, —S—, —C(O)— and —S(O) 2 —;
L is a divalent linker of the following formula:
—(CH 2 ) m —(OCH 2 CH 2 ) n —O—(CH 2 ) p —

wherein:
m is 2 or 3;
n is 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19 or 20; and
p is 2 or 3;

B is selected from the group consisting of a detection moiety, an anti-cancer agent, and a heat shock protein 90 binding component; and
R is selected from the group consisting of —H and a detection moiety;
wherein each heat shock protein 90 binding component independently has the following formula (II):

wherein:
R 1 and R 2 are independently selected from the group consisting of —H and —C 1-8 -alkyl;
Y is CR 3 or N;
R 3 is —H, —F or —OCH 3 ;
R 4 and R 5 are independently selected from the group consisting of —H, —F and —OCH 3 ;
R 6 is —C 1-8 -alkyl, —C 2-8 -alkenyl, —C 2-8 -alkynyl, —C 3-8 -cycloalkenyl, —C 3-8 -cycloalkenyl-C 1-8 -alkyl, —C 3-8 -cycloalkyl, —C 3-8 -cycloalkyl-C 1-8 -alkyl, aryl, aryl-C 1-8 -alkyl, halo-C 1-8 -alkyl, heteroaryl, heteroaryl-C 1-8 -alkyl, heterocyclyl, heterocyclyl-C 1-8 -alkyl, or hydroxy-C 1-8 -alkyl;
R 7 and R 8 are independently selected from the group consisting of —H and —C 1-8 -alkyl;
X is N;
and

represents the point of attachment in formula (I);
wherein each detection moiety independently comprises a fluorophore or a radioactive compound;
wherein the fluorophore is a fluorescein, a rhodamine, a coumarin, a cyanine, or a boron-dipyrromethene;
wherein the radioactive compound is a radioisotope; and
wherein the anti-cancer agent is an alkylating agent, an anti-epidermal growth factor receptor antibody, an anti-Her-2 antibody, an antimetabolite, a vinca alkaloid, an anthracycline, a platinum-based agent, a topoisomerase inhibitor, a taxane, an anti-cancer antibiotic, an immune cell antibody, an interferon, an interleukin, a heat shock protein 90 inhibitor, an anti-androgen, an anti-estrogen, an antihypercalcemia agent, an apoptosis inducer, an aurora kinase inhibitor, a Bruton's tyrosine kinase inhibitor, a calcineurin inhibitor, a Ca 2+ -calmodulin-dependent protein kinase II inhibitor, a CD45 tyrosine phosphatase inhibitor, a cell division cycle 25 phosphatase inhibitor, a checkpoint kinase inhibitor, a cyclooxygenase inhibitor, a cRAF kinase inhibitor, a cyclin dependent kinase inhibitor, a cysteine protease inhibitor, a deoxyribonucleic acid intercalator, a deoxyribonucleic acid strand breaker, an E3 ligase inhibitor, an epidermal growth factor pathway inhibitor, a farnesyltransferase inhibitor, a fetal liver kinase-1 inhibitor, a glycogen synthase kinase-3 inhibitor, a histone deacetylase inhibitor, an I-kappa B-alpha kinase inhibitor, an imidazotetrazinone, an insulin tyrosine kinase inhibitor, a c-Jun N-terminal kinase inhibitor, a mitogen-activated protein kinase inhibitor, a mouse double minute 2 inhibitor, an MEK inhibitor, a matrix metalloproteinase inhibitor, a mammalian target of rapamycin inhibitor, a nerve growth factor receptor tyrosine kinase inhibitor, a p38 mitogen-activated protein kinase inhibitor, a p56 tyrosine kinase inhibitor, a platelet-derived growth factor pathway inhibitor, a phosphatidylinositol 3-kinase inhibitor, a phosphatase inhibitor, a protein phosphatase inhibitor, a protein kinase C inhibitor, a protein kinase C delta kinase inhibitor, a polyamine synthesis inhibitor, a protein tyrosine phosphatase 1B inhibitor, a protein tyrosine kinase inhibitor, an SRC family tyrosine kinase inhibitor, a spleen tyrosine kinase inhibitor, a Janus tyrosine kinase inhibitor, a retinoid, a ribonucleic acid polymerase II elongation inhibitor, a serine/threonine kinase inhibitor, a sterol biosynthesis inhibitor, a vascular endothelial growth factor pathway inhibitor, alitretinon, altretamine, aminopterin, aminolevulinic acid, amsacrine, asparaginase, atrasentan, bexarotene, carboquone, demecolcine, efaproxiral, elsamitrucin, etoglucid, a Gliadel implant, hydroxycarbamide, leucovorin, lonidamine, lucanthone, masoprocol, methyl aminolevulinate, mitoguazone, mitotane, oblimersen, omacetaxine, pegaspargase, porfimer sodium, prednimustine, sitimagene ceradenovec, talaporfin, temoporfin, trabectedin or verteporfin.

2. The compound of claim 1 , wherein A has the formula:

3. The compound of claim 1 , wherein B is a detection moiety.

4. The compound of claim 3 , wherein B is a fluorophore.

5. The compound of claim 1 , wherein B is an anti-cancer agent.

6. The compound of claim 1 , wherein B is a heat shock protein 90 binding component.

7. The compound of claim 1 , wherein:
R 1 and R 2 are independently —H;
Y is CR 3 ;
R 3 is —H;
R 4 and R 5 are independently —H;
R 6 is —C 1-8 -alkyl or halo-C 1-8 -alkyl; and
R 7 and R 8 are independently —C 1-8 -alkyl.

8. The compound of claim 1 , wherein m is 3 and p is 3.

9. The compound of claim 1 , wherein n is 4.

10. A kit comprising a compound of claim 1 .

Assignees

• Univ Duke

Inventors

• Haystead Timothy
• Hughes Philip Floyd

Classifications

• G01N33/57595

  involving intracellular compounds · CPC title

• G01N33/575

  for cancer · CPC title

• G01N2333/47

  Assays involving proteins of known structure or function as defined in the subgroups · CPC title

• C07D473/34 Primary

  attached in position 6, e.g. adenine · CPC title

• C07D413/12

  linked by a chain containing hetero atoms as chain links · CPC title